Joseph Arulandu, MD
Internal Medicine · la Porte, INNPI 1316952807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $154,685 of the $250,860 with a category attached, or 61.7%. 60 manufacturers reported payments, led by Novo Nordisk at 41.6% of the total. Reporting peaked in 2019 at $89,213 and has fallen 93.3% since, to $5,993 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,098 payments — averaging $119.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$104K
- Amarin Pharma, Inc.$34K
- Bayer$32K
- Esperion Therapeutics, Inc.$28K
- AstraZeneca$15K
- Sanofi-aventis U.S. LLC$14K
- plus $24K from 54 others
What the payments were for
- Consulting fees$45,94918%
- Speaking & faculty fees$154,68562%
- Travel & lodging$14,6686%
- Food & beverage$35,25914%
- Education$2990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$32,805
- Kerendia$29,104
- NEXLIZET$26,817
- NEXLETOL$26,817
- Ozempic$24,072
- RYBELSUS$22,615
- Victoza$22,380
- Tresiba$16,589
- FARXIGA$12,160
- DISEASE STATE$5,173
- SOLIQUA 100/33$4,471
- Xultophy 100/3.6$3,082
- TOUJEO$1,327
- Non-Covered$1,159
- XARELTO$587
- INPEN SMART INSULIN DELIVERY SYSTEM$517
- MINIMED 770G$426
- UBRELVY$350
- PRALUENT$129
- BREZTRI$125
How this compares
$250,860 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 142 | $204,415 |
| TrulicityDulaglutide | 147 | $165,281 |
| JardianceEmpagliflozin | 139 | $163,763 |
| FarxigaDapagliflozin Propanediol | 107 | $105,125 |
| EliquisApixaban | 100 | $98,486 |
| XareltoRivaroxaban | 65 | $76,431 |
| MounjaroTirzepatide | 72 | $75,334 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $68,733 |
| InvokanaCanagliflozin | 21 | $31,790 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,302 |
| VraylarCariprazine Hcl | 15 | $22,130 |
| SynjardyEmpagliflozin/Metformin Hcl | 29 | $21,867 |
| RybelsusSemaglutide | 12 | $20,823 |
| KerendiaFinerenone | 19 | $19,930 |
| EntrestoSacubitril/Valsartan | 21 | $19,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,242 | $245,609239 claims |
| Novo NordiskOzempic, Rybelsus | $104,238 | $225,238154 claims |
| Boehringer IngelheimJardiance, Synjardy, Combivent Respimat | $1,471 | $203,393190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $14,611 | $142,647179 claims |
| Johnson & JohnsonXarelto, Invokana | $1,410 | $108,22086 claims |
| PfizerEliquis | $1,410 | $98,486100 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $913 | $75,68697 claims |
| AbbVieVraylar, Linzess, Synthroid | $3,526 | $39,753118 claims |
| BayerKerendia | $31,641 | $19,93019 claims |
| NovartisEntresto | $861 | $19,81821 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $219 | $18,62913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $673 | $12,87713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in la Porte
- Vinay Tumulurila Porte$23K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.